The Experts below are selected from a list of 58158 Experts worldwide ranked by ideXlab platform
Peter S. Fail - One of the best experts on this subject based on the ideXlab platform.
-
novel Simultaneous Combination chemical thrombolysis rheolytic thrombectomy therapy for acute critical limb ischemia the power pulse spray technique
Catheterization and Cardiovascular Interventions, 2004Co-Authors: David E. Allie, Chris J. Hebert, Mitchell D. Lirtzman, Charles H. Wyatt, Mohamed H. Khan, Esmond A. Barker, M.w. Mcelderry, Muhammad A. Khan, Antoine V Keller, Peter S. FailAbstract:The novel power-pulse spray (P-PS) technique maximizes and combines the advantages and minimizes the disadvantages of both chemical thrombolysis (CT) and rheolytic thrombectomy (RT). Forty-nine consecutive patients with iliofemoral thrombotic occlusion were treated via P-PS technique. Using a 6 Fr RT catheter, saline prime was exchanged for thrombolytic solution [group 1, 10-20 mg tenecteplase (TNK)/50 cc saline, n = 25; group 2, 1,000,000 urokinase (UK)/50 cc saline, n = 24]. The outflow port was closed, then the catheter was advanced at 1 mm increments while pulsing lytic agent. After 30-min lysis time, RT and definitive treatment of the underlying stenosis were performed. Procedure success was 23/25 (92%) and 22/24 (91.6%) for group 1 and 2, respectively. The mean total procedure time was 72 and 75 min in group 1 and 2, respectively. Thirty-day limb salvage was 91% in both groups. There were no major surgical complications. The P-PS technique is safe and effective using either UK or TNK, offering several potential advantages over monotherapy, including more rapid revascularization, decreases systemic lytic exposure and bleeding complications while facilitating both CT and RT capacity and efficacy.
-
Novel Simultaneous Combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: The power‐pulse spray technique
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004Co-Authors: David E. Allie, Chris J. Hebert, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. Khan, Esmond A. Barker, M.w. Mcelderry, Muhammad A. Khan, Peter S. FailAbstract:The novel power-pulse spray (P-PS) technique maximizes and combines the advantages and minimizes the disadvantages of both chemical thrombolysis (CT) and rheolytic thrombectomy (RT). Forty-nine consecutive patients with iliofemoral thrombotic occlusion were treated via P-PS technique. Using a 6 Fr RT catheter, saline prime was exchanged for thrombolytic solution [group 1, 10-20 mg tenecteplase (TNK)/50 cc saline, n = 25; group 2, 1,000,000 urokinase (UK)/50 cc saline, n = 24]. The outflow port was closed, then the catheter was advanced at 1 mm increments while pulsing lytic agent. After 30-min lysis time, RT and definitive treatment of the underlying stenosis were performed. Procedure success was 23/25 (92%) and 22/24 (91.6%) for group 1 and 2, respectively. The mean total procedure time was 72 and 75 min in group 1 and 2, respectively. Thirty-day limb salvage was 91% in both groups. There were no major surgical complications. The P-PS technique is safe and effective using either UK or TNK, offering several potential advantages over monotherapy, including more rapid revascularization, decreases systemic lytic exposure and bleeding complications while facilitating both CT and RT capacity and efficacy.
Kevin Croussore - One of the best experts on this subject based on the ideXlab platform.
-
Phase-Regenerative Wavelength Conversion for BPSK and DPSK Signals
IEEE Photonics Technology Letters, 2009Co-Authors: Kevin CroussoreAbstract:Phase-regenerative wavelength conversion is demonstrated experimentally. The Simultaneous Combination of two nonlinear optical processes, phase conjugation and frequency conversion (Bragg scattering), produces phase-sensitive gain at two new idler wavelengths in addition to the original signal wavelength. This single-stage approach does not require phase-locking of the tunable pump. At maximum pump depletion, amplitude and phase regeneration occur Simultaneously.
Guido Bocci - One of the best experts on this subject based on the ideXlab platform.
-
Synergistic efficacy of irinotecan and sunitinib Combination in preclinical models of anaplastic thyroid cancer.
Cancer letters, 2017Co-Authors: Teresa Di Desidero, Anna Fioravanti, Paola Orlandi, Greta Alì, Gabriella Fontanini, Alessandro Antonelli, Silvia Martina Ferrari, Fulvio Basolo, Giulio Francia, Guido BocciAbstract:Abstract The identification of new therapeutic strategies is urgently needed for the management of patients affected by anaplastic thyroid cancer (ATC) due to their short survival and poor prognosis. Aim of the study was to determine the activity of the Combination irinotecan/sunitinib on ATC cell growth in vitro and the antitumor effects in vivo. Proliferation assays were performed for 72 h on ATC cell lines exposed to the Combination of SN-38, the active metabolite of irinotecan, and sunitinib. The Simultaneous Combination of sunitinib and SN-38, quantified by the Combination index, determined a high synergism on ATC cells, increasing the intracellular concentrations of SN-38. Moreover, the synergistic Combination greatly decreases the gene expression and the protein levels of vascular endothelial growth factor, colony stimulating factor 1 and ATP-binding cassette transporter G2 in ATC cells. A significant in vivo antitumor effect was observed in ATC xenografts with the Simultaneous Combination of irinotecan and sunitinib if compared to monotherapy. The Simultaneous Combination of irinotecan and sunitinib, in vitro and in vivo demonstrated a significant, synergistic ATC antitumor activity, suggesting a possible and rapid translation of this schedule into the clinics.
-
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo.
Oncology research, 2017Co-Authors: Antonello Di Paolo, Paola Orlandi, Teresa Di Desidero, Romano Danesi, Guido BocciAbstract:The Combination of folinate salts to 5-fluoruracil (5-FU)-based schedules is an established clinical routine in the landscape of colorectal cancer treatment. The aim of this study was to investigate the pharmacological differences between the sequential administration of folinate salts (1 h before, as in clinical routine) followed by 5-FU and the Simultaneous administration of both drugs. Proliferation and apoptotic assays were performed on human colon cancer cells exposed to 5-FU, calcium (CaLV), or disodium (NaLV) levofolinate or their Simultaneous and sequential Combination for 24 and 72 h. TYMS and SLC19A1 gene expression was performed with real-time PCR. In vivo experiments were performed in xenografted nude mice, which were treated with 5-FU escalating doses and CaLV or NaLV alone or in Simultaneous and sequential Combination. The Simultaneous Combination of folinate salts and 5-FU was synergistic (NaLV) or additive (CaLV) in a 24-h treatment in both cell lines. In contrast, the sequential Combination of both folinate salts and 5-FU was antagonistic at 24 and 72 h. The Simultaneous Combination of 5-FU and NaLV or CaLV inhibited TYMS gene expression at 24 h, whereas the sequential Combination reduced SLC19A1 gene expression. In vivo experiments confirmed the enhanced antitumor activity of the 5-FU + NaLV Simultaneous Combination with a good toxicity profile, whereas the sequential Combination with CaLV failed to potentiate 5-FU activity. In conclusion, only the Simultaneous, but not the consecutive, in vitro and in vivo Combination of 5-FU and both folinate salt formulations potentiated the antiproliferative effects of the drugs.
-
Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo
Neoplasia (New York N.Y.), 2011Co-Authors: Bastianina Canu, Anna Fioravanti, Paola Orlandi, Teresa Di Desidero, Greta Alì, Gabriella Fontanini, Antonello Di Paolo, Mario Del Tacca, Romano Danesi, Guido BocciAbstract:Aims: To demonstrate the synergistic antiproliferative and proapoptotic activity of irinotecan and axitinib in vitro and the improvement of the in vivo effects on angiogenesis and pancreatic cancer. Methods: Proliferation and apoptotic assays were performed on human dermal microvascular endothelial cells and pancreas cancer (MIAPaCa-2, Capan-1) cell lines exposed to SN-38, the active metabolite of irinotecan, axitinib, or their Simultaneous Combination for 72 hours. ERK1/2 and Akt phosphorylation, the vascular endothelial growth factor (VEGF), VEGF receptor-2, and thrombospondin-1 (TSP-1) concentration were measured by ELISAs. ATP7A and ABCG2 gene expression was performed with real-time polymerase chain reaction and SN-38 intracellular concentrations were measured by high-performance liquid chromatography. Capan-1 xenografts in nude mice were treated with irinotecan and axitinib alone or in Simultaneous Combination. Results: A strong synergistic effect on antiproliferative and proapoptotic activity was found with the axitinib/SN-38 Combination on endothelial and cancer cells. ERK1/2 and Akt phosphorylation were significantly inhibited by lower concentrations of the combined drugs in all the cell lines. Axitinib and SN-38 combined treatment greatly inhibited the expression of the ATP7A and ABCG2 genes in endothelial and cancer cells, increasing the SN-38 intracellular concentration. Moreover, TSP-1 secretion was increased in cells treated with both drugs, whereas VEGFR-2 levels significantly decreased. In vivo administration of the Simultaneous Combination determined an almost complete regression of tumors and tumor neovascularization. Conclusions: In vitro results show the highly synergistic properties of Simultaneous Combination of irinotecan and axitinib on endothelial and pancreas cancer cells, suggesting a possible translation of this schedule into the clinics.
Kenji Jinno - One of the best experts on this subject based on the ideXlab platform.
-
Simultaneous Combination of endoscopic sclerotherapy and endoscopic ligation for esophageal varices.
Gastrointestinal endoscopy, 1995Co-Authors: Yoshiyuki Nishikawa, Yasushi Hosokawa, Toshihiko Doi, Syuji Shima, Masatsugu Miyoshi, Tohru Ohnishi, Masato Tanimizu, Ichinosuke Hyodo, Kenji JinnoAbstract:Endoscopic injection sclerotherapy (EIS) is an established standard t reatment for esophageal varices 1, 2; however, EIS entails complicated manipulation. Endoscopic variceal ligation (EVL) ~-5 has been increasingly performed because of the safety and simplicity of the technique because no sclerosant is used. To accomplish rapid eradication of the varices and prevent recurrence, a technique that combines EVL and EIS has also been performed. 6, 7 For more effective and simple EIS, we developed a method that Simultaneously combines EVL and EIS (endoscopic injection sclerotherapy with ligation: EISL). EIS was performed after application of the EVL device, and EVL was performed (including the injection site) immediately after infusion of the sc]erosant. This technique may be more effective because of better sclerosant effect after interruption of blood flow s and the absence of bleeding after removal of the needle.
David E. Allie - One of the best experts on this subject based on the ideXlab platform.
-
novel Simultaneous Combination chemical thrombolysis rheolytic thrombectomy therapy for acute critical limb ischemia the power pulse spray technique
Catheterization and Cardiovascular Interventions, 2004Co-Authors: David E. Allie, Chris J. Hebert, Mitchell D. Lirtzman, Charles H. Wyatt, Mohamed H. Khan, Esmond A. Barker, M.w. Mcelderry, Muhammad A. Khan, Antoine V Keller, Peter S. FailAbstract:The novel power-pulse spray (P-PS) technique maximizes and combines the advantages and minimizes the disadvantages of both chemical thrombolysis (CT) and rheolytic thrombectomy (RT). Forty-nine consecutive patients with iliofemoral thrombotic occlusion were treated via P-PS technique. Using a 6 Fr RT catheter, saline prime was exchanged for thrombolytic solution [group 1, 10-20 mg tenecteplase (TNK)/50 cc saline, n = 25; group 2, 1,000,000 urokinase (UK)/50 cc saline, n = 24]. The outflow port was closed, then the catheter was advanced at 1 mm increments while pulsing lytic agent. After 30-min lysis time, RT and definitive treatment of the underlying stenosis were performed. Procedure success was 23/25 (92%) and 22/24 (91.6%) for group 1 and 2, respectively. The mean total procedure time was 72 and 75 min in group 1 and 2, respectively. Thirty-day limb salvage was 91% in both groups. There were no major surgical complications. The P-PS technique is safe and effective using either UK or TNK, offering several potential advantages over monotherapy, including more rapid revascularization, decreases systemic lytic exposure and bleeding complications while facilitating both CT and RT capacity and efficacy.
-
Novel Simultaneous Combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: The power‐pulse spray technique
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004Co-Authors: David E. Allie, Chris J. Hebert, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. Khan, Esmond A. Barker, M.w. Mcelderry, Muhammad A. Khan, Peter S. FailAbstract:The novel power-pulse spray (P-PS) technique maximizes and combines the advantages and minimizes the disadvantages of both chemical thrombolysis (CT) and rheolytic thrombectomy (RT). Forty-nine consecutive patients with iliofemoral thrombotic occlusion were treated via P-PS technique. Using a 6 Fr RT catheter, saline prime was exchanged for thrombolytic solution [group 1, 10-20 mg tenecteplase (TNK)/50 cc saline, n = 25; group 2, 1,000,000 urokinase (UK)/50 cc saline, n = 24]. The outflow port was closed, then the catheter was advanced at 1 mm increments while pulsing lytic agent. After 30-min lysis time, RT and definitive treatment of the underlying stenosis were performed. Procedure success was 23/25 (92%) and 22/24 (91.6%) for group 1 and 2, respectively. The mean total procedure time was 72 and 75 min in group 1 and 2, respectively. Thirty-day limb salvage was 91% in both groups. There were no major surgical complications. The P-PS technique is safe and effective using either UK or TNK, offering several potential advantages over monotherapy, including more rapid revascularization, decreases systemic lytic exposure and bleeding complications while facilitating both CT and RT capacity and efficacy.
